Clinical Trial Update: Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer [Phase 1]

View source ↗

Summary

Phase Ib feasibility neoadjuvant trial of nivolumab plus lirilumab for cisplatin-ineligible muscle-invasive bladder cancer has completed enrollment with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• lirilumab (lirilumab)
• nivolumab (nivolumab)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Bladder Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-09-01